vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and ReposiTrak, Inc. (TRAK). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $5.9M, roughly 1.6× ReposiTrak, Inc.). ReposiTrak, Inc. runs the higher net margin — 28.8% vs -60.3%, a 89.1% gap on every dollar of revenue. On growth, ReposiTrak, Inc. posted the faster year-over-year revenue change (6.7% vs -49.9%). ReposiTrak, Inc. produced more free cash flow last quarter ($2.2M vs $1.6M). Over the past eight quarters, ReposiTrak, Inc.'s revenue compounded faster (7.3% CAGR vs -6.7%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
ReposiTrak, Inc. offers cloud-based supply chain management, food safety and regulatory compliance solutions for the retail, foodservice and consumer packaged goods sectors. Its platform helps clients trace products, mitigate supply chain risks, meet industry safety standards, and boost operational efficiency, with core operations focused on North American markets.
PLX vs TRAK — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $5.9M |
| Net Profit | $-5.5M | $1.7M |
| Gross Margin | 49.4% | 85.4% |
| Operating Margin | -51.1% | 31.0% |
| Net Margin | -60.3% | 28.8% |
| Revenue YoY | -49.9% | 6.7% |
| Net Profit YoY | -184.8% | 8.7% |
| EPS (diluted) | $-0.06 | $0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $5.9M | ||
| Q3 25 | $17.9M | $6.0M | ||
| Q2 25 | $15.7M | $5.8M | ||
| Q1 25 | $10.1M | $5.9M | ||
| Q4 24 | $18.2M | $5.5M | ||
| Q3 24 | $18.0M | $5.4M | ||
| Q2 24 | $13.5M | $5.2M | ||
| Q1 24 | — | $5.1M |
| Q4 25 | $-5.5M | $1.7M | ||
| Q3 25 | $2.4M | $1.8M | ||
| Q2 25 | $164.0K | $1.8M | ||
| Q1 25 | $-3.6M | $2.0M | ||
| Q4 24 | $6.5M | $1.6M | ||
| Q3 24 | $3.2M | $1.7M | ||
| Q2 24 | $-2.2M | $1.6M | ||
| Q1 24 | — | $1.6M |
| Q4 25 | 49.4% | 85.4% | ||
| Q3 25 | 53.4% | 85.7% | ||
| Q2 25 | 62.5% | 84.2% | ||
| Q1 25 | 19.1% | 84.6% | ||
| Q4 24 | 78.7% | 81.7% | ||
| Q3 24 | 53.4% | 84.2% | ||
| Q2 24 | 29.8% | 83.7% | ||
| Q1 24 | — | 83.6% |
| Q4 25 | -51.1% | 31.0% | ||
| Q3 25 | 11.9% | 31.7% | ||
| Q2 25 | 7.5% | 27.5% | ||
| Q1 25 | -41.0% | 30.6% | ||
| Q4 24 | 39.6% | 24.6% | ||
| Q3 24 | 22.2% | 27.2% | ||
| Q2 24 | -18.0% | 25.5% | ||
| Q1 24 | — | 24.8% |
| Q4 25 | -60.3% | 28.8% | ||
| Q3 25 | 13.2% | 30.5% | ||
| Q2 25 | 1.0% | 31.2% | ||
| Q1 25 | -35.8% | 33.2% | ||
| Q4 24 | 35.6% | 28.2% | ||
| Q3 24 | 18.0% | 30.6% | ||
| Q2 24 | -16.4% | 30.5% | ||
| Q1 24 | — | 30.5% |
| Q4 25 | $-0.06 | $0.09 | ||
| Q3 25 | $0.03 | $0.09 | ||
| Q2 25 | $0.00 | $0.09 | ||
| Q1 25 | $-0.05 | $0.10 | ||
| Q4 24 | $0.10 | $0.08 | ||
| Q3 24 | $0.03 | $0.08 | ||
| Q2 24 | $-0.03 | $0.07 | ||
| Q1 24 | — | $0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | — |
| Total DebtLower is stronger | — | $170.4K |
| Stockholders' EquityBook value | $48.2M | $49.7M |
| Total Assets | $82.3M | $56.3M |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | — | ||
| Q3 25 | $13.6M | — | ||
| Q2 25 | $17.9M | — | ||
| Q1 25 | $19.5M | — | ||
| Q4 24 | $19.8M | — | ||
| Q3 24 | $27.4M | — | ||
| Q2 24 | $23.4M | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $170.4K | ||
| Q3 25 | — | $225.0K | ||
| Q2 25 | — | $278.7K | ||
| Q1 25 | — | $331.8K | ||
| Q4 24 | — | $384.1K | ||
| Q3 24 | — | $165.7K | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | — |
| Q4 25 | $48.2M | $49.7M | ||
| Q3 25 | $52.9M | $50.2M | ||
| Q2 25 | $49.9M | $49.5M | ||
| Q1 25 | $45.2M | $48.9M | ||
| Q4 24 | $43.2M | $47.9M | ||
| Q3 24 | $32.4M | $47.5M | ||
| Q2 24 | $28.6M | $46.9M | ||
| Q1 24 | — | $46.5M |
| Q4 25 | $82.3M | $56.3M | ||
| Q3 25 | $82.3M | $55.6M | ||
| Q2 25 | $78.5M | $55.3M | ||
| Q1 25 | $73.9M | $54.8M | ||
| Q4 24 | $73.4M | $54.7M | ||
| Q3 24 | $61.6M | $52.3M | ||
| Q2 24 | $91.5M | $51.6M | ||
| Q1 24 | — | $51.3M |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.01× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.01× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $2.2M |
| Free Cash FlowOCF − Capex | $1.6M | $2.2M |
| FCF MarginFCF / Revenue | 17.8% | 38.2% |
| Capex IntensityCapex / Revenue | 4.4% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.33× |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $6.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $2.2M | ||
| Q3 25 | $-3.7M | $1.5M | ||
| Q2 25 | $-5.2M | $1.7M | ||
| Q1 25 | $-5.1M | $1.4M | ||
| Q4 24 | $4.0M | $3.5M | ||
| Q3 24 | $4.1M | $1.9M | ||
| Q2 24 | $-3.6M | $2.1M | ||
| Q1 24 | — | $2.5M |
| Q4 25 | $1.6M | $2.2M | ||
| Q3 25 | $-4.2M | $1.5M | ||
| Q2 25 | $-5.7M | $1.6M | ||
| Q1 25 | $-5.4M | $1.4M | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $4.0M | — | ||
| Q2 24 | $-3.8M | $2.0M | ||
| Q1 24 | — | $2.5M |
| Q4 25 | 17.8% | 38.2% | ||
| Q3 25 | -23.7% | 25.6% | ||
| Q2 25 | -36.2% | 28.6% | ||
| Q1 25 | -53.0% | 24.1% | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 22.4% | — | ||
| Q2 24 | -28.1% | 38.5% | ||
| Q1 24 | — | 48.2% |
| Q4 25 | 4.4% | 0.0% | ||
| Q3 25 | 2.8% | 0.2% | ||
| Q2 25 | 2.8% | 0.1% | ||
| Q1 25 | 3.0% | 0.1% | ||
| Q4 24 | 2.3% | 0.0% | ||
| Q3 24 | 0.5% | 0.0% | ||
| Q2 24 | 1.3% | 1.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | 1.33× | ||
| Q3 25 | -1.58× | 0.85× | ||
| Q2 25 | -31.91× | 0.92× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 0.61× | 2.23× | ||
| Q3 24 | 1.27× | 1.12× | ||
| Q2 24 | — | 1.30× | ||
| Q1 24 | — | 1.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
TRAK
| Subscription And Support | $5.7M | 98% |
| Other | $141.2K | 2% |
